{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Globus Medical, Inc.
Is Globus Medical, Inc. overvalued or undervalued?
As of October 31, 2025, Globus Medical, Inc. is considered overvalued with a valuation grade of "attractive," reflected by a P/E ratio of 36 and a year-to-date return of -25.45%, significantly underperforming the S&P 500's 16.30%.
Globus Medical Experiences Valuation Adjustment Amid Competitive Market Landscape
Globus Medical, Inc. has recently adjusted its valuation, with its current price at $61.20. The company has faced challenges over the past year, reporting a return of -18.27%. Key financial metrics include a P/E ratio of 36 and a price-to-book value of 1.98, indicating its market position.
Is Globus Medical, Inc. overvalued or undervalued?
As of October 31, 2025, Globus Medical, Inc. is considered attractive but overvalued, with a P/E ratio of 36 compared to the peer average of 18.37, and has underperformed the S&P 500 with a year-to-date return of -26.01%.
Is Globus Medical, Inc. overvalued or undervalued?
As of October 31, 2025, Globus Medical, Inc. is considered attractive but overvalued, with a P/E ratio of 36 and a year-to-date return of -26.99%, significantly underperforming the S&P 500's gain of 16.30%.
Is Globus Medical, Inc. overvalued or undervalued?
As of October 31, 2025, Globus Medical, Inc. is considered attractive but overvalued with a P/E ratio of 36 compared to the peer average of 18.37, and it has underperformed the S&P 500 with a year-to-date return of -26.99%.
Is Globus Medical, Inc. overvalued or undervalued?
As of October 17, 2025, Globus Medical, Inc. is considered attractive but overvalued with a high P/E ratio of 36 compared to the peer average of 18.37, has underperformed the S&P 500 with a year-to-date return of -27.97%, and shows a low PEG ratio of 0.54, indicating caution for potential investors.
Globus Medical Experiences Valuation Adjustment Amid Competitive Market Landscape
Globus Medical, Inc. has recently adjusted its valuation, with a P/E ratio of 36 and a Price to Book Value of 1.98. The company has outperformed the S&P 500 in the short term but has faced significant year-to-date and one-year declines, contrasting with its peers in the sector.
Is Globus Medical, Inc. overvalued or undervalued?
As of October 17, 2025, Globus Medical, Inc. is considered overvalued due to high P/E and EV/EBITDA ratios compared to peers, alongside underperformance against the S&P 500, leading to a valuation grade downgrade from very attractive to attractive.
Is Globus Medical, Inc. overvalued or undervalued?
As of October 17, 2025, Globus Medical, Inc. is considered attractive but overvalued with a P/E ratio of 36 and a year-to-date return of -27.97%, underperforming the S&P 500's 13.30%.
Globus Medical Experiences Revision in Stock Evaluation Amid Mixed Market Signals
Globus Medical, Inc. has recently experienced a stock price adjustment, currently at $60.17. The stock has shown significant volatility over the past year, with a high of $94.93 and a low of $51.79. Performance metrics indicate mixed signals, with varying trends across different indicators and a notable decline year-to-date.
Is Globus Medical, Inc. technically bullish or bearish?
As of October 3, 2025, Globus Medical, Inc. shows a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 with a year-to-date return of -27.25% compared to 14.18%.
Is Globus Medical, Inc. technically bullish or bearish?
As of October 3, 2025, Globus Medical, Inc. shows a mildly bearish technical trend, with mixed indicators across different timeframes and a year-to-date return of -26.88%, significantly underperforming the S&P 500's 14.18%.
Is Globus Medical, Inc. technically bullish or bearish?
As of October 3, 2025, Globus Medical, Inc. shows a mildly bearish technical trend with mixed signals across various indicators, underperforming the S&P 500 with a year-to-date return of -26.88%.
Is Globus Medical, Inc. technically bullish or bearish?
As of August 8, 2025, Globus Medical, Inc. is in a mildly bearish trend, with mixed technical indicators and significant underperformance compared to the S&P 500, showing a year-to-date return of -31.39% versus the index's 12.22%.
Is Globus Medical, Inc. overvalued or undervalued?
As of August 22, 2025, Globus Medical, Inc. is considered overvalued with a P/E ratio of 36 compared to the industry average of 18.37, and its stock has underperformed the S&P 500 with a year-to-date return of -31.39%.
Is Globus Medical, Inc. overvalued or undervalued?
As of June 16, 2025, Globus Medical, Inc. is fairly valued with a P/E ratio of 36, making it a potentially attractive investment compared to peers like Inspire Medical Systems, while showing potential for recovery despite recent underperformance.
Is Globus Medical, Inc. technically bullish or bearish?
As of June 18, 2025, Globus Medical, Inc. shows a bearish trend with moderate strength, supported by bearish signals from the weekly MACD, Bollinger Bands, and daily moving averages, despite mixed signals from the KST and Dow Theory.
Who are in the management team of Globus Medical, Inc.?
As of March 2022, the management team of Globus Medical, Inc. includes Executive Chairman David Paul, President and CEO David Demski, and several independent directors: David Davidar, Robert Douglas, Daniel Lemaitre, Ann Rhoads, and James Tobin.
What does Globus Medical, Inc. do?
Globus Medical, Inc. is a mid-cap medical device company specializing in products for musculoskeletal and spine disorders, with recent net sales of $598 million and a net profit of $75 million. The company has a market cap of approximately $7.87 billion.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
